ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-04 19:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 125.4 KB | ||
| 2021-02-03 10:11 |
Franchissement de seuil
|
French | 261.7 KB | ||
| 2021-01-25 22:30 |
ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position
|
English | 291.7 KB | ||
| 2021-01-25 22:30 |
ERYTECH rappelle les principales échéances cliniques attendues en 2021 et publi…
|
French | 320.6 KB | ||
| 2021-01-14 22:30 |
ERYTECH annonce le recrutement du premier patient dans une étude de phase 1 con…
|
French | 791.2 KB | ||
| 2021-01-14 22:30 |
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Tr…
|
English | 650.1 KB | ||
| 2021-01-12 18:27 |
Franchissement de seuil
|
French | 204.3 KB | ||
| 2021-01-07 17:45 |
Franchissement de seuil
|
French | 198.7 KB | ||
| 2021-01-07 17:44 |
Franchissement de seuil
|
French | 204.8 KB | ||
| 2021-01-06 22:30 |
ERYTECH tiendra une présentation à l’occasion de la conférence virtuelle H.C. W…
|
French | 255.0 KB | ||
| 2021-01-06 22:30 |
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
|
English | 219.9 KB | ||
| 2021-01-06 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 203.7 KB | ||
| 2021-01-06 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 135.0 KB | ||
| 2021-01-04 08:00 |
ERYTECH tiendra une présentation lors de la 10ème édition du LifeSci Partners H…
|
French | 733.0 KB | ||
| 2021-01-04 08:00 |
ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Acc…
|
English | 619.5 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
